Human sex hormone-binding globulin (SHBG) transports sex steroids in the blood. It functions as a homodimer, but there is little information about the topography of its dimerization domain, and its steroid binding stoichiometry is controversial. The prevailing assumption is that each homodimeric SHBG molecule contains a single steroid-binding site at the dimer interface. However, crystallographic analysis of the aminoterminal laminin G-like domain of human SHBG has shown that the dimerization and steroid-binding sites are distinct and that both monomers within a homodimeric complex are capable of binding steroid. To validate our crystallographic model of the SHBG homodimer, we have used site-directed mutagenesis to create SHBG variants in which single amino acid substitutions (V89E and L122E) were introduced to produce steric clashes at critical positions within the proposed dimerization domain. The resulting dimerization-deficient SHBG variants contain a steroid-binding site with an affinity and specificity indistinguishable from wildtype SHBG. Moreover, when equalized in terms of their monomeric subunit content, dimerization-deficient and wild-type SHBGs have essentially identical steroid binding capacities. These data indicate that both subunits of the SHBG homodimer bind steroid and that measurements of the molar concentration of SHBG homodimer in serum samples have been overestimated by 2-fold.
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Human sex hormone-binding globulin (SHBG)
1 is a homodimeric plasma glycoprotein that regulates the access of testosterone and estradiol to their target tissues (1) . There is a considerable amount of information about the location of amino acid residues within the SHBG steroid-binding site (2-4), but little is known about the location and topography of the homodimer interface. Recently, it has become possible to resolve these issues in the context of a detailed understanding of the tertiary structure of the amino-terminal laminin G4-like (LG4) domain of human SHBG (5) . This region of human SHBG comprises the steroid-binding site, as well as residues important for dimer formation (3, 6) , and crystal structure analysis has revealed a potential interface between two SHBG LG4 domains that could account for the homodimerization of SHBG monomers (5) .
Measurements of the steroid binding capacity and protein concentration of purified SHBG have led to the prevailing opinion that an equimolar relationship exists between SHBG homodimer and steroid ligand (7) , and this has supported the notion that a single steroid-binding site is located within the dimer interface (8) . However, our crystal structure data indicated that amino acid residues within what appears to be the most likely dimer interface do not participate in steroid binding and that each monomer of the SHBG homodimer contains a steroid-binding site (5) .
It is known that SHBG monomers interact very strongly (K d about 10 Ϫ12 M) with each other (9) and can be effectively dissociated only under denaturing conditions such as treatment with guanidinium chloride (10) . There is also evidence that dimer formation is promoted in the presence of steroid ligand (6) . Consequently, it has been virtually impossible to determine whether each monomer binds steroid or if the process of dimerization somehow creates a single high affinity steroid-binding site. Although a homodimeric preparation of the human SHBG LG4 domain was used for crystal structure determination (11) , and the steroid-binding sites in each subunit of this structure were completely occupied (5), these complexes were obtained in the presence of a great excess of steroid ligand. Under these conditions, both steroid-binding sites may have been artificially saturated. Therefore, we could not exclude the possibility that dimer formation somehow blocks the access of ligand to one binding site or substantially reduces the binding affinity of one site within the homodimer under physiological conditions.
The crystal structure of the human SHBG LG4 domain suggested that dimerization occurs through ␤-strand pairing between strands ␤7 of one monomer and ␤10 of another (5) . In this configuration, a 2-fold symmetry axis across the dimer interface allows ␤-strand pairing to be repeated with the formation of a large hydrophobic interaction patch at the center of the proposed interface. To test this model, we created a series of SHBG variants containing amino acid substitutions that would cause steric clashes at predicted points of interaction between SHBG monomers and thereby disrupt dimer formation. In this way, we have been able to verify the topography of the dimerization interface, and the dimerization-deficient SHBG variants we produced have allowed us to demonstrate unequivocally that the SHBG homodimer contains two high affinity steroid-binding sites.
EXPERIMENTAL PROCEDURES
Crystallographic Analysis of the SHBG Homodimer Interface-Analysis of the dimerization interface was based on the 1.55 Å crystal structure 2 of the human SHBG LG4 domain (residues 1-205) in complex with 5␣-dihydrotestosterone (DHT) (PDB:1D2S). Model visualizations were performed with program O (12) . Accessible surface areas were calculated with program AREAIMOL of the CCP4 program suite (13) using a solvent probe radius of 1.4 Å.
Production of Human SHBG Variants-A cDNA encoding the human SHBG precursor 3 was inserted into a pSelect-1 phagemid (Promega) for site-directed mutagenesis (14) . The oligonucleotide primer sequences for mutagenesis were: V89E, 5Ј-TGGTCCAGCACCCTCCGTAAGCT-GGGC; A85S/V89E/A91S, 5Ј-TCTCCCATCATCCAGCCGTGGTCCA-GAACCCTCCGTAAGCTGGGACCAGTGTAAGTGCAGTTGGATCTC; L122E, 5Ј-TGTCTCAGGCGCTCCACCTCCTCCCCATC; Q126A, 5Ј-AGGGGCCCAGAGACTGCTCTCAGGCGCAGCA (the altered nucleotides are underlined). The mutated cDNAs were subcloned into a pRc/ CMV eukaryotic expression vector (Invitrogen) and sequenced to confirm that only the targeted mutations were present. The resulting plasmids were used for transfection of Chinese hamster ovary cells (CHO pro Ϫ , wild type) using LipofectAMINE reagent (Life Technologies, Inc.) according to the protocol suggested by the manufacturer. After selection in the presence of G418 (Life Technologies, Inc.), stably transformed cells were grown to near confluence, washed twice with phosphate-buffered saline to remove fetal bovine serum, and were then cultured in serum-free Dulbecco's modified Eagle's medium (Life Technologies, Inc.) for 2-4 days. Cell culture medium from CHO cells expressing wild-type (14) and mutated human SHBG cDNAs were collected, concentrated using Ultrafree 15 devices (Amicon), and dialyzed overnight at 4°C in Slide-a-lyzers (Sigma) against 100 volumes of 20 mM Tris-HCl, pH 7.5, 100 mM NaCl containing 1 mM CaCl 2 and 1 M DHT.
Steroid Binding Assays-A standard saturation analysis method employing dextran-coated charcoal (DCC) as a separation agent and [ 3 H]DHT (42 Ci/mmol, PerkinElmer Life Sciences) as labeled ligand was used to determine the steroid binding capacity, affinity, and specificity of SHBG (15) . To compare the steroid binding capacities of wild-type SHBG and dimerization-deficient SHBG variants, the concentrations of SHBG monomers in samples were equalized based on their immunoreactivity on a Western blot prior to steroid binding assays.
Western Blotting-Proteins were resolved by polyacrylamide gel electrophoresis (PAGE) under non-denaturing or denaturing conditions and transferred to Hybond-ECL nitrocellulose membranes (Amersham Pharmacia Biotech) by electroblotting. The blots were blocked and then incubated with 1:500 diluted rabbit anti-human SHBG antiserum (16) , and immunoreactive proteins were visualized with the ECL Western blotting system (Amersham Pharmacia Biotech) as recommended by the manufacturer. Blots were scanned with a ScanJet 5370C scanner (Hewlett-Packard) and quantified using ImageQuaNT software (Molecular Dynamics).
Gel Filtration-Gel filtration chromatography of concentrated cell culture media containing wild-type SHBG or dimerization-deficient SHBG variants was performed using an FPLC system (Amersham Pharmacia Biotech). Samples (150 -200 l) were loaded onto a 1 ϫ 30-cm Superdex 75 column equilibrated with 20 mM Tris-HCl, pH 7.0, 500 mM NaCl, 1 M DHT, 0.05% NaN 3 , and calibrated using gel filtration marker proteins (Amersham Pharmacia Biotech). Elution was performed with the same buffer, and 250-l fractions were collected and analyzed for steroid binding activity by Western blotting.
Steroid Affinity Adsorption-To verify that wild-type SHBG and the dimerization-deficient SHBG variants produced by CHO cells were equally capable of binding steroid ligand, we used a steroid affinity matrix to adsorb them from the culture medium. This was also done to exclude the possibility that some undefined fraction of these recombinant products lacked steroid binding activity. To this end, 300 l of concentrated culture medium, containing either wild-type SHBG or SHBG variants, was first treated with a DCC pellet to remove steroid and was then incubated (2 h at room temperature) with 30 l of 5␣-dihydrotestosterone-17␣-hexanoic acid-Sepharose (HAHA-Sepharose) (17) . After centrifugation for 5 min at 10,000 ϫ g, samples of the supernatants were taken for a steroid binding capacity assay and Western blotting. In this way, the amounts of SHBG in these samples were compared using two independent methods against samples of the corresponding proteins prior to affinity adsorption. Furthermore, to assess nonspecific adsorption of proteins to the affinity resin, similar experiments were performed either in the presence of 1 M DHT or with Sepharose CL-4B instead of the affinity resin.
RESULTS AND DISCUSSION
Resolution of the SHBG Homodimer Interface-Analysis of the human SHBG LG4 domain crystal structure indicated that homodimerization occurs through a 2-fold symmetry axis located at the edge of the ␤-sheet sandwich of each SHBG monomer (Fig. 1) . This symmetry axis places strand ␤7 of one monomer next to strand ␤10 of the other monomer and vice versa. As a consequence, the main chain hydrogen bond pairing characteristic for ␤-sheets extends across the interface, and two contiguous 14-stranded ␤-sheets are generated in the SHBG homodimer (5). In total, 8 main chain-main chain hydrogen bonds are formed across the interface, and 24 residues from each monomer participate in the process of dimerization with each monomer contributing about 760 Å 2 to the interface surface. Contributions are from four different segments of the SHBG LG4 domain, i.e. from the loop connecting strand ␤5 to ␤6, from strand ␤7, from strand ␤10, and from the large insertion between strands ␤11 and ␤12 (Fig. 2) . However, strands ␤7 and ␤10 account for about 580 Å 2 (76%) of the interface surface and far exceed the contributions of the other segments.
The central region of the interface is very hydrophobic in nature and involves residues Ala-85, Leu-87, Val-89, Leu-122, and Leu-124, which are strictly conserved in SHBG from dif-2 PDB number: 1D2S. 3 GenBank™ Accession Number NM_001040. FIG. 1. a, proposed model for (25, 26) . ferent species, as well as the largely conserved residues Ala-91 and Val-121 (18). The hydrophobic core is surrounded by inter-␤-sheet main chain:main chain hydrogen bonds, as well as a number of hydrophilic side chain contacts provided for example by residues Arg-75, Glu-120, Arg-125, Gln-126, and Arg-154 (Fig. 1) . The side chain of each of these residues contributes more than 40 Å 2 to the interface. The contribution of single amino acids to the affinity of interaction between proteins often correlates poorly with the surface area that individual amino acids contribute to the interaction (19). In addition, in the case of SHBG, the dimer interface contains numerous main chain-main chain interactions. Thus, we anticipated that it would be difficult to abolish SHBG dimer formation by removing side chain-side chain interactions through the substitution of individual amino acids with alanine. Instead, we opted to disrupt the dimer interface by introducing larger side chains, which would cause severe steric clashes at the proposed dimerization interface. In this context, residues Val-89 and Leu-122, as well as Ala-85 and Ala-91, which are located in the center of the hydrophobic core region of the interface, were identified as the most promising candidates for substitution, and we therefore prepared the following SHBG variants: V89E, L122E, and A85S/V89E/A91S. In addition, previous data suggest a possible role for the large loop connecting strands ␤11 to ␤12 in the dimerization of human SHBG (3). Two residues from this segment, namely Arg-154 and Leu-155, are located within the dimerization site (Fig.  2) , and Arg-154 contacts Gln-126 at the dimer interface. Accordingly, an SHBG Q126A variant was also produced to evaluate the possible contribution of this residue to dimer formation.
This model of the homodimer interface is based on crystal structure data obtained using only the first 205 residues of human SHBG produced in bacteria, and it does not take into account any possible influences that glycosylation or the carboxyl-terminal LG5 domain might have on dimer formation. To circumvent this shortcoming, all the SHBG variants we have studied were produced in mammalian cells as fully glycosylated, intact SHBG molecules. The ability of these SHBG variants to form homodimers was also assessed by two independent methods, namely Western blotting after electrophoresis under non-denaturing conditions and gel filtration chromatography.
The Western blot analysis (Fig. 3) shows that the Q126A SHBG variant migrates as a dimeric protein similar to wildtype SHBG during PAGE under non-denaturing conditions, whereas the A85S/V89E/A91S, V89E, and L122E SHBG variants have an increased electrophoretic mobility consistent with the presence of only a monomer (3). Thus, although contacts between Arg-154 and Gln-126 are not critical for dimer formation, disruption of the hydrophobic patch between strands ␤7 and ␤10 completely abolishes dimerization (Fig. 3) , and this was confirmed by gel filtration chromatography (Fig. 4) . The chromatographic profile shown in Fig. 4 clearly indicates that the hydrodynamic properties of the SHBG V89E dimerizationdeficient variant are consistent with a molecular mass of ϳ48 kDa. By contrast, the elution volume of wild-type SHBG corresponds to a homodimer with a molecular mass of ϳ100 kDa, which agrees with a previous report (17) . The latter experiment in which chromatography fractions were monitored for steroid binding activity also provided the first evidence that dimerization-deficient mutants are capable of binding steroid.
Taken together, these results indicate that the hydrophobic patch at the center of the dimer interface plays a predominant role in the homodimerization of SHBG. Our data also indicate that appropriate dimerization will not occur if this region contains amino acids with larger side chains. We therefore conclude that the hydrophobic side chains pack tightly within the dimer interface and that the interface shape complementarity is high. Moreover, these data are consistent with our predicted structure of the intact human SHBG homodimer (5) and its rod-shaped appearance on electron micrographs (20) .
Although our data do not preclude involvement of the LG5 domain of SHBG in the dimerization process, any such contribution must be minor. However, the LG5 domain may influence the overall stability of the homodimer in some way because removal of steroid destabilizes SHBG LG4 homodimers much more effectively (6) than full-length SHBG produced in mammalian cells or purified from blood (3). It is therefore possible that occupancy of the steroid-binding site alters the conformation of the dimerization interface and that this is less constrained in the absence of the LG5 domain. To date, we have been unable to obtain a crystal structure of the SHBG LG4 domain in the absence of ligand, and this may be due to the presence of a heterogeneous mixture of incomplete or unstable dimers. The availability of dimerization-deficient human SHBG variants may help resolve this problem. If crystallization of the dimerization-deficient variants can be accomplished, it may be possible to resolve any conformational changes that occur upon steroid binding and that indirectly enhance dimer formation.
Homodimeric SHBG Contains Two Steroid-binding SitesThe assumption that human SHBG contains only a single high affinity steroid-binding site is based primarily on comparative measurements of the steroid binding capacity and protein concentration of purified human SHBG (16) . However, the dye binding assays used to determine the concentrations of pure SHBG are subject to error (21) , and the question of its steroid binding stoichiometry has never been adequately investigated. The availability of dimerization-deficient SHBG variants has FIG. 2. Surface area contributed by individual amino acids to the dimer interface. The values were calculated from differences in the solvent accessibility of individual amino acids in the context of the monomer and the dimer. As indicated in the upper part of the graph, residues from four different segments of SHBG contribute to the interface. The secondary structure designation is as defined previously (5), and the numbering of residues refers to their position in the mature polypeptide (7) .   FIG. 3. Western blot of wild-type SHBG (lane 1) and the following SHBG variants: V89E (lane 2), A85S/V89E/A91S (lane 3),  L122E (lane 4), and Q126A (lane 5) . Proteins were separated under non-denaturing conditions by PAGE using 4 and 7.5% acrylamide in the stacking and resolving gels, respectively. enabled us to address this issue in a manner that does not rely on conventional protein concentration measurements. This was accomplished by comparing the steroid binding capacities of wild-type SHBG and SHBG dimerization-deficient variants after equalization of their molar concentrations with respect to monomer content (Fig. 5 ). On this Western blot, the concentrations of SHBG monomers present in samples of the wild-type homodimer (lane 1) and the dimerization-deficient variants (lanes 2-4) have been equalized based on their immunoreactivity by appropriate dilution. It could be argued that the immunoreactivity of mutant monomers may be impaired, but this is unlikely because all protein samples were denatured prior to PAGE, and all three dimerization-deficient variants exhibit essentially identical immunoreactivity with respect to their steroid binding capacity (Fig. 5) .
Under denaturing conditions, SHBG migrates as two major electrophoretic isoforms (22) , which reflects differences in Nlinked glycosylation within the carboxyl-terminal LG5 domain (14) . In this context, it is of interest that the electrophoretic microheterogeneity of the V89E and A85S/V89E/A91S SHBG variants resembles that of wild-type SHBG, whereas the two main electrophoretic isoforms of the L122E SHBG variant migrate differently, consistent with a difference in N-linked glycosylation (Fig. 5 ). This suggests that amino acid substitutions within the LG4 domain can influence the processing of Nlinked oligosaccharides within the LG5 domain, but this has no effect on dimerization (Fig. 3) or steroid binding (Fig. 5) .
More importantly, when these samples of wild-type SHBG and the dimerization-deficient variants containing equal concentrations of the SHBG monomer were compared with respect to their steroid binding capacities, these were within 5% of each other (Fig. 5) . Although these data indicate that each monomer within the homodimer has essentially the same steroid binding capacity as the dimerization-deficient SHBG variants, we also considered the possibility that a portion of the dimerizationdeficient variants might be defective and lack steroid binding activity. However, this was excluded by the complete and specific adsorption of both wild-type SHBG and SHBG V89E by a steroid-affinity resin (Fig. 6) . Furthermore, in contrast to the micromolar concentrations of steroid ligand used to obtain SHBG crystals (11) , these analyses employed nanomolar concentrations of steroids, and we obtained no evidence for more than one class of steroid-binding site in wild-type SHBG or the dimerization-deficient SHBG variants by Scatchard analysis (data not shown). There was also no difference in their steroid binding affinities or ligand specificity (Table I) . Thus, these data allow us to conclude for the first time that the human SHBG homodimer contains two equally active steroid-binding sites and to raise some interesting issues related to the biological function of human SHBG. For instance, they suggest that the two steroid-binding sites within the SHBG homodimer can be partially occupied or even occupied by different classes of steroid ligands. These possibilities need to be considered particularly in the context of ligand-dependent interactions between SHBG and plasma membrane proteins, which have been proposed to play a role in the non-genomic mechanism of steroid hormone action (23) .
Measurements of serum SHBG levels are widely used in the evaluation of clinical conditions associated with androgen excess because they provide an indication of the amount of free testosterone in the blood (24) . Diagnostic assays used for this purpose are based largely on immunoassays, which are standardized using reference samples calibrated in terms of their steroid binding capacity. Although the serum levels of SHBG based on these assays provide a true reflection of the steroid binding capacity of SHBG in the samples, the molar concentrations of homodimeric SHBG have been overestimated by a factor of 2.
